Pain and therapy · 2026
Long-Term Efficacy and Safety of Treatments for Chronic Peripheral Neuropathic Pain: A Systematic Review and Narrative Synthesis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eerdekens Mariëlle H, Both Charlotte, Freitas Rita L
Аннотация
INTRODUCTION: Peripheral neuropathic pain (PNP) is a chronic condition that often requires long-term treatment. In 2025, the Neuropathic Pain Special Interest Group (NeuPSIG) updated its recommendations for treatment of neuropathic pain based on data from double-blind, randomized controlled trials (RCTs) with a duration of ≥ 3 weeks. To complement the existing body of evidence, we reviewed the long-term efficacy/safety of NeuPSIG-recommended treatments for PNP.
METHODS: We conducted a systematic literature review including clinical trials and observational studies of any design. Two literature searches were performed using PubMed and Embase (December 2024, May 2025). We included studies that enrolled ≥ 50 adult patients with PNP receiving ≥ 1 treatment recommended in the 2025 NeuPSIG guidance and with duration of ≥ 13 weeks. A supplemental search for long-term studies on high-concentration capsaicin 8% patch (HCCP) was performed. Results were synthesized narratively due to heterogeneity in study designs and outcomes.
RESULTS: We included 34 articles in our analysis (31 studies) varying in design, including interventional (RCTs and open-label studies) and observational studies. Most studies had a duration of 26-52 weeks. Four treatments (HCCP, duloxetine, gabapentin, pregabalin) were evaluated in ≥ 5 studies. HCCP was evaluated in the greatest number of long-term studies (n = 13) and in various PNP conditions, followed by duloxetine (n = 7) in painful diabetic peripheral neuropathy (pDPN) only, gabapentin (n = 6) in various PNP conditions and pregabalin (n = 5) mostly in pDPN. Collected data support long-term efficacy of all products. The lowest rates of discontinuations due to adverse events were reported with HCCP.
CONCLUSIONS: The findings from this literature review emphasize the importance of expanding long-term evidence for chronic pain therapies. The review determined that the largest body of evidence is available for HCCP. Finally, it highlights the need for more standardized long-term evidence studies for chronic pain therapies.
METHODS: We conducted a systematic literature review including clinical trials and observational studies of any design. Two literature searches were performed using PubMed and Embase (December 2024, May 2025). We included studies that enrolled ≥ 50 adult patients with PNP receiving ≥ 1 treatment recommended in the 2025 NeuPSIG guidance and with duration of ≥ 13 weeks. A supplemental search for long-term studies on high-concentration capsaicin 8% patch (HCCP) was performed. Results were synthesized narratively due to heterogeneity in study designs and outcomes.
RESULTS: We included 34 articles in our analysis (31 studies) varying in design, including interventional (RCTs and open-label studies) and observational studies. Most studies had a duration of 26-52 weeks. Four treatments (HCCP, duloxetine, gabapentin, pregabalin) were evaluated in ≥ 5 studies. HCCP was evaluated in the greatest number of long-term studies (n = 13) and in various PNP conditions, followed by duloxetine (n = 7) in painful diabetic peripheral neuropathy (pDPN) only, gabapentin (n = 6) in various PNP conditions and pregabalin (n = 5) mostly in pDPN. Collected data support long-term efficacy of all products. The lowest rates of discontinuations due to adverse events were reported with HCCP.
CONCLUSIONS: The findings from this literature review emphasize the importance of expanding long-term evidence for chronic pain therapies. The review determined that the largest body of evidence is available for HCCP. Finally, it highlights the need for more standardized long-term evidence studies for chronic pain therapies.